Evaluation of folded amniotic membrane and injectable amniotic membrane pieces as soft tissue filler materials

Buday, Mustafa Caglar; Öztürk, Murat

doi:10.1016/j.anl.2018.10.014

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It counts with the presence of important cells of the point of view of regenerative medicine-such as mesenchymal stromal cells (MSCs), and fibroblasts-a wide array of cell growth factors, proteins, proteoglycans and cytokines (Farhadihosseinabadi et al 2018) and secretes peptides with antimicrobial character (Tehrani et al 2017). In the last years, it has been studied for the repair of peripheral nerve defects (Bourgeois et al 2019, Zhang et al 2019, full-thickness skin (Song et al 2017), wound diabetic ulcerations (Paggiaro et al 2018), ophthalmological conditions (Navas et al 2018), burns (Puyana et al 2020), intrauterine adhesion due to endometrial fibrosis (Chen et al 2019), osteoinductive (Tang et al 2018), cartilage grafts (Motamed et al 2019), soft tissue filling (Buday and Ozturk 2019), associated with colistin and silver nanoparticles to treat infected burns in animal model (Wali et al 2022), among others. In addition, its application as a scaffold for cells (Dragúňová et al 2019), as drug-delivery systems (Mencucci et al 2011) and organ-on-chip technology (Richardson et al 2020) are promising for clinical therapies.…”

Section: Introductionmentioning

confidence: 99%

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Naasani¹,

Pretto²,

Zanatelli³

et al. 2022

Biofabrication

View full text Add to dashboard Cite

Therapies to deep burn injuries remain a global challenge. Human amniotic membrane (hAM) is a biomaterial that has been increasingly explored by the field of regenerative medicine. A decellularized hAM (DhAM) can be used as scaffold for mesenchymal stromal cells (MSCs) to grow without the loss of their stemness potential, allowing its application as cell therapy for wound healing. In this work, we associated DhAM with adipose-derived mesenchymal stromal cells (DhAM+AD-MSC), as a therapy strategy for second-degree burns in a preclinical model . Animals with induced second-degree burns were divided into 4 groups: control, which consists of a non-adherent gauze; a synthetic commercial dressing as the positive control (control+); DhAM; and DhAM plus rat AD-MSCs (DhAM+AD-MSCs), followed by detailed and long term analysis (5 weeks). The macroscopical analysis showed the healing improvement in the wound area after the DhAM+AD-MSC treatment. Histological analysis also showed no alteration in the animal organs and a regular epithelial progression in comparison to the control. This observation was also confirmed by the analysis of suprabasal layers in the neoepidermis with CK10, showing a stratified and differentiated epithelium, when compared to Control and Control+. A strong CD73 (ecto-5′-nucleotidase) labeling was observed in the first two weeks postburn in dermis and epidermis. The expression in dermis was stronger in the second week in the middle of the wound, when comparing the Control+ with DhAM+AD-MSCs (p=0.0238). In the epidermis the expression of CD73 was increased in all regions when compared to the control. This data suggests the involvement of this protein on wound healing. A low CD11b labeling was observed in DhAM+AD-MSCs treatment group mainly in the last treatment week, in comparison to Control and Control+ (p<0.0001), which indicates a reduction in the inflammatory process. MSCs through CD73 can release high concentrations of adenosine, an immunosuppressive molecule, suggesting that this could be the mechanism by which the inflammation was better modulated in the DhAM+AD-MSCs group. The results obtained with this preclinical model confirm the effectiveness and safety of this low-cost and highly available dressing for future clinical application as a therapy for burn treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Naasani¹,

Pretto²,

Zanatelli³

et al. 2022

Biofabrication

View full text Add to dashboard Cite

show abstract

“…Recent research by Buday and Ozturk, who transplanted amniotic membrane pieces into the soft tissue of rats’ backs, showed the use of the membrane for injection material without foreign body reaction, necrosis, or fibrosis. Furthermore, the use of amniotic membrane for soft tissue filler was concluded in this study as the membrane held its presence, augmenting the tissue into which it was transplanted [10].…”

Section: Introductionmentioning

confidence: 99%

Amniotic Allograft Implantation for Midface Aging Correction: A Retrospective Comparative Study with Platelet-Rich Plasma

Davis¹,

Augenstein²

2019

Aesth Plast Surg

View full text Add to dashboard Cite

Amniotic allografts are becoming more popular for use in soft tissue growth in many areas of medicine because of their immunoprivilege that allows them to proliferate into tissues without rejection by the host. Platelet-rich plasma (PRP) has crossed over from wide orthopedic uses to the aesthetic market for hair restoration and midface volume replacement, owing, in part, to the minimal risk associated with the procedure and the convenience of in-office application. In addition, growth factors provided by PRP help stimulate collagen synthesis in the aging face. However, the potential recruitment of the patient’s own mesenchymal stem cells to the PRP injection site would produce the most favorable and sustained aesthetic outcome. With the advancement of amniotic allograft procedures, the introduction of live mesenchymal cells of the amniotic membrane into the aging midface could be performed in-office similarly to the PRP treatment. This retrospective chart review compares aspects of the amniotic allograft procedure (office time, level of comfort, and downtime) with the aesthetic results of injection into the midface of those undergoing PRP therapy. Analysis of the changes to midface volume, specifically the Ogee curve, observed in the chronological progression of photographs illustrates aesthetic improvements in both PRP and amnion allograft treatment groups, with changes in the facial grading scale. Less patient downtime and slightly more rapid improvements were noted in the amnion group in comparison with the PRP treatment participants.Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

show abstract

“…In other clinical trials, micronized dehydrated human amnion/chorion membrane (μ-dHACM, EpiFix®) was also shown to be effective in treating diabetic foot ulcers, plantar fasciitis, and osteoarthritis (OA) with minimal invasiveness [ 16 – 19 ]. More recently, the Amnio-M was used as an effective dermal filler for facial wrinkles to restore smooth skin appearance in an in vivo rabbit model [ 20 ]. Its cosmetic applications showed rapid improvement in midface aging correction cases, including filling the nasolabial folds, malar fat pad, and descent of lid skin below the orbital rim [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Applications of the amniotic membrane in tissue engineering and regeneration: the hundred-year challenge

et al. 2022

View full text Add to dashboard Cite

The amniotic membrane (Amnio-M) has various applications in regenerative medicine. It acts as a highly biocompatible natural scaffold and as a source of several types of stem cells and potent growth factors. It also serves as an effective nano-reservoir for drug delivery, thanks to its high entrapment properties. Over the past century, the use of the Amnio-M in the clinic has evolved from a simple sheet for topical applications for skin and corneal repair into more advanced forms, such as micronized dehydrated membrane, amniotic cytokine extract, and solubilized powder injections to regenerate muscles, cartilage, and tendons. This review highlights the development of the Amnio-M over the years and the implication of new and emerging nanotechnology to support expanding its use for tissue engineering and clinical applications. Graphical Abstract

show abstract

Evaluation of folded amniotic membrane and injectable amniotic membrane pieces as soft tissue filler materials

Cited by 4 publications

References 8 publications

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Amniotic Allograft Implantation for Midface Aging Correction: A Retrospective Comparative Study with Platelet-Rich Plasma

Applications of the amniotic membrane in tissue engineering and regeneration: the hundred-year challenge

Contact Info

Product

Resources

About